Paolo Tarantino: We’re running SATEEN, the first trial of sacituzumab govitecan + trastuzumab in patients with HER2 + MBC
Paolo Tarantino, Medical Oncologist and Research Fellow at Dana-Farber Cancer Institute, shared a post by Marta Perachino, Medical Oncology Resident at San Martino Polyclinic on X, adding:
“Highly Trop2 expressing HER2+ tumors appear resistant to chemo/HER2-blockade. Could a Trop2 ADC work well instead? At Dana-Farber’s Breast Oncology Center, we’re running SATEEN, the first trial of sacituzumab govitecan + trastuzumab in patients with HER2+ MBC. Currently enrolling. ”
Quoting Marta Perachino`s post:
“Trop-2 expression and pCR in eBC HER2+: retrospective analysis of PHERgain 41 patients evaluable Trop-2: 17 low, 14 intermediate, 10 high Trop-2 H-score less likely to obtain a pCR OR 0.03; 95% CI, 0.001–0.290, p adjusted < 0.01.”
Read further.
Source: Paolo Tarantino/X and Marta Perachino/X